Curtana Pharmaceuticals

Biopharma, Biotechnology, Health Care, Pharmaceutical
Founded in 2013-01-01
Austin, Texas, United States
http://www.curtanapharma.com
For Profit

About Curtana Pharmaceuticals

Curtana Pharmaceuticals was founded on a mission to develop the first truly targeted therapies for the treatment of the most aggressive types of brain cancer. The company’s drug development program is based on the pioneering research of Dr. Santosh Kesari, who is currently the Chairman of the Department of Translational Neuro-oncology and Neuro-therapeutics at the John Wayne Cancer Institute. Curtana’s senior leadership brings years of experience in the pharmaceutical industry, with extensive backgrounds in the development of new molecular entities for the treatment of cancer as well as CNS disorders. Curtana initiated operations in San Diego, California in 2013. Following the award of a highly prestigious and competitive grant ($7.6M) from the Cancer Prevention and Research Institute of Texas (CPRIT) in August 2014, the company relocated its lab and offices to Austin, Texas. Current investors include Thynk Capital, angelMD, Biosense Global, DEFTA Partners, and other anonymous investors.

Company Metrics

  • Employees: 1-10
  • Monthly Visits: 493
  • Tech Stack: 10 active products

Financial Information

  • Estimated Revenue: $1M to $10M
  • Total Funding: 50000 EUR
  • Last Funding: 50000 EUR (Grant)
  • Funding Status: Seed

Technology Stack

Curtana Pharmaceuticals actively uses 10 products in their tech stack.

Market Presence

Industries: Biopharma, Biotechnology, Health Care, Pharmaceutical

Headquarters: Austin, Texas, United States